As such, we similarly investigated the effects of combining midostaurin with the same chemotherapy agents and proviability signalling molecule inhibitors against wt FLT3‐expressing AML cell lines that display a broad range of sensitivity to standard chemotherapy and targeted inhibitors such as venetoclax as single agents (Figures 6 and S9). The gene discussed is FLT3; the disease is acute myeloid leukemia.